Showing results (1021-1030 of 2,413) with videos related to
Sort By:
Pageof 242
Journal of Medical Economics|August 1, 2012
Patient and parent preferences for immunoglobulin treatments: a conjoint analysisAteesha F Mohamed, Vikram Kilambi, Michelle P Luo, et al.Journal of Medical Economics|September 13, 2012
Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German settingJ U Blohmer, M Rezai, S Kümmel, et al.Journal of Medical Economics|September 14, 2012
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancerLaure Benjamin, Valérie Buthion, Michaël Iskedjian, et al.Journal of Medical Economics|August 21, 2020
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payersNirmish R Shah, Menaka Bhor, Dominick Latremouille-Viau, et al.Journal of Medical Economics|June 19, 2012
Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO studyDaniela Paola Roggeri, Sandro Mazzaferro, Diego Brancaccio, et al.Journal of Medical Economics|June 21, 2012
A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish settingMatthew Prettyjohns, Rebecka Sandelin, Steven Lister, et al.Journal of Medical Economics|April 2, 2015
Effectiveness of step therapy policies for specialty pharmaceuticals in immune disordersChris M Kozma, Mike Ingham, Andy Paris, et al.Journal of Medical Economics|May 5, 2023
Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in ChinaWeijia Wu, Shuyi Ding, Zhang Mingming, et al.Journal of Medical Economics|May 1, 2023
Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysisCharly Gaul, Karolin Seidel, Alexander Heuck, et al.Journal of Medical Economics|January 29, 2015
Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitisKabirraaj Toor, Eric Druyts, Jeroen P Jansen, et al.Pageof 242